Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Stoa Announces Additional $100 Million Raised to Help Real Estate Investors Flip Homes Faster
-
Critical Elements complete Positive Engineering Study for a Lithium Hydroxide Monohydrate Plant
-
Westwater Resources, Inc. Announces Results for Second Quarter Ended June 30, 2022
-
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
-
Aytu BioScience (AYTU) Prices Public Offering of Common Stock, Warrants
-
Aytu BioPharma Announces Pricing of Public Offering
-
Heron Therapeutics (HRTX) Announces 16.13M Share Private Placement at $3.10/sh
-
Heron Therapeutics Announces $76.5 Million Private Placement Financing
-
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
-
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
-
Cybin Announces Up to USD$35 Million At-The-Market Equity Program
-
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
-
View Announces Q2 Earnings, Reaffirms 2022 Guidance and Provides Update on Financing; Dynamic Glass Investment Tax Credit included in the Climate package of the Senate Passed Inflation Reduction Act
-
View Announces Q2 Earnings, Reaffirms 2022 Guidance and Provides Update on Financing; Dynamic Glass Investment Tax Credit included in the Climate package of the Senate Passed Inflation Reduction Act
-
Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Aytu BioScience (AYTU) Announces Public Offering
-
Aytu BioPharma Announces Launch of Public Offering
-
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
-
Wall St Week Ahead: Inflation data may seal fate of unloved U.S. stock rally
-
Orchid Island Capital Announces Second Quarter 2022 Results
-
Poseida Therapeutics (PSTX) Prices 20M Share Offering at $3.50/sh
-
Poseida Therapeutics Announces Pricing of Public Offering of Common Stock
-
Poseida Therapeutics (PSTX) Announces Proposed Stock Offering, Size not Disclosed
-
Poseida Therapeutics Announces Proposed Public Offering of Common Stock
-
Form 8-K Cantor Fitzgerald Income For: Aug 01
-
Poseida Therapeutics (PSTX) Announces Proposed Stock Offering, Size not Disclosed
-
Poseida Therapeutics Announces Proposed Public Offering of Common Stock
-
"We Encourage Investors to Acquire SPNE Shares" - Cantor Fitzgerald SeaSpine (SPNE) at Overweight with $21 Price Target
-
UPDATE: Tilray (TLRY) PT Lowered to $4.15 at Cantor Fitzgerald
-
Pfizer (PFE) Earnings Growth 'Underappreciated' - Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Downgrades ObsEva (OBSV) to Neutral
-
Cantor Fitzgerald Income Trust, Inc. Closes $118 Million Dollars in Real Estate Related Acquisitions
-
StoneX Group (SNEX) Launches Institutional Credit Offering in Asia
-
StoneX Launches Institutional Credit Offering in Asia
-
Cantor Fitzgerald Reiterates Overweight Rating, $215 Price Target on Johnson & Johnson (JNJ) Post Earnings
-
Form 424B3 Cantor Fitzgerald Income
-
UPDATE: Cantor Fitzgerald Assumes Arcturus Therapeutics (ARCT) at Overweight
-
Form EFFECT Cantor Fitzgerald Income
-
EYP-1901 Peak Sales Opportunity is Underappreciated - Cantor Fitzgerald Reiterates EyePoint (EYPT) at Overweight
-
Cantor Fitzgerald Launches Cantor Fitzgerald Sustainable Infrastructure Fund
-
Cantor Fitzgerald Assumes Alaunos Therapeutics Inc. (TCRT) at Overweight
-
Sanara MedTech (SMTI) PT Raised to $50 at Cantor Fitzgerald Post Accretive Scendia Acquisition, Encourage Investors to Acquire Undervalued Shares
-
IDB BANK APPOINTS KENNETH SAVIO AS NEW CEO OF IDB CAPITAL
-
Cantor Fitzgerald Downgrades ContraFect (CFRX) to Neutral, Lowers PT to $1 from $15
-
Orchid Island Capital Announces Estimated Second Quarter 2022 Results, July 2022 Monthly Dividend and June 30, 2022 RMBS Portfolio Characteristics
-
Form POS AM Cantor Fitzgerald Income
-
Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX) Following Latest Nu.Q Data
-
Cantor Fitzgerald Reiterates Neutral Rating, $1 Price Target on TherapeuticsMD (TXMD) on Failed Acquisition

